Andrés Finzi and Christian Baron
Andrés Finzi and Christian Baron
A team from the CHUM Research Centre and Université de Montréal has identified a molecule that, in the lab, can inhibit the COVID-19 variants of concern.
In the spring of 2020, Université de Montréal biochemistry professor Christian Baron had an idea: why not evaluate the inhibition capacity of a commercially available molecule called VE607 on the virus causing COVID-19?
VE607 was first identified in 2004 to fight SARS, a close cousin of SARS-CoV-2. Given the rapid end of SARS infections, its development was prematurely abandoned.
Seeing an opportunity to bring it back to life in the fight against a new pandemic, Baron spoke to his UdeM colleague Andrés Finzi, a virologist at the university’s teaching hospital research centre, the CRCHUM.
“I must admit that I didn’t believe in it at first,” recalled Finzi, holder of the Canada Research Chair in Retroviral Entry and professor at UdeM in the Department of Microbiology, Infectiology and Immunology.
“We had already tried to reuse other existing molecules and the results were mixed. But since then we discovered that VE607 works very well with all the SARS-CoV-2 variants—Alpha, Beta, Gamma, Delta and Omicron, all of them were inhibited.”
In a new, non-peer-reviewed study posted on the bioRxiv prepublication server, Baron, Finzi and collaborators demonstrated that VE607 attaches to the virus spike (S protein), the “key to entry of the virus,” freezing it in a particular conformation and thus preventing it from unlocking the door of healthy cells and infecting them.
Tests on humans at least a year away
In their study, done in collaboration with colleagues at the University of Ottawa and four U.S. universities, the two co-authors and their lab teams also found that VE607 stabilizes the receptor-binding domain (RBD) in its “up” conformation.
That’s important, they said, because it could explain why the variants were inhibited, as RBD is a key component of the virus that allows it to dock with the body’s receptors to enter cells.
“Bringing to light the efficacy of this new coronavirus inhibitor opens the way to the development of new drugs for the prevention or treatment of COVID-19-related infections,” said Baron. “It should take at least one year to optimize the inhibition capacity and to do tests on humans.”
Finzi and Baron’s work was supported financially in part by UdeM’s Faculty of Medicine, through its Combattre la COVID-19: de la prévention au contrôle fund, highlighting the importance of the philanthropy of donors to the faculty.
“This type of funding is invaluable, as it is often used as leverage to advance scientific discovery,” said Ekat Kritikou, the faculty’s vice-dean of research and development. The VE607 discovery “is a great example of a breakthrough that can help develop new therapeutic approaches to combat COVID-19.”
About this study
“VE607 stabilizes SARS-CoV-2 spike in the ‘RBD-up’ conformation and inhibits viral entry,” by Andrés Finzi, Christian Baron et al, was published Feb. 4, 2022 in bioRxiv. Funding was provided by the Canadian Institutes of Health Research, the Fonds de recherche du Québec—Santé, the Ministère de l’Économie et de l’Innovation du Québec, the Canada Foundation for Innovation, the Fondation du CHUM, the Fondation J.-Louis Lévesque and the Faculty of Medicine of Université de Montréal.